Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341417 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
NCT02341417 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 28 participants.
The verdict
NCT02341417, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
Study Summary
The primary objective of this study was to characterize the long-term safety and tolerability of cinacalcet in pediatric patients with chronic kidney disease (CKD) receiving dialysis.
Interventions
- DRUG Cinacalcet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-06-10 |
| Est. Completion | 2017-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02341417
The ClinicalTrials.gov registry entry for NCT02341417 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cinacalcet is the first listed.
NCT02341417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02341417 about?
NCT02341417 is a clinical study titled "Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis". The primary objective of this study was to characterize the long-term safety and tolerability of cinacalcet in pediatric patients with chronic kidney disease (CKD) receiving dialysis.
What is the current status of trial NCT02341417?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2015-06-10. Estimated completion is 2017-03-15.
What interventions are being tested in trial NCT02341417?
The interventions under investigation include: Cinacalcet (DRUG).
Who is sponsoring clinical trial NCT02341417?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.